Use of Tranexamic Acid in Reduction Mammoplasty

• Status: Recruiting
• Trial end date: 2022-07-13
• Target enrollment: 0
• Participant gender: Female

Summary

Breast reduction mammoplasty (BRM) is among the most commonly performed procedures in plastic surgery. However, postoperative hematoma is one of the most common complications following BRM. Hematoma-related complications include unplanned surgery, need for blood transfusion, wound healing issues, and unfavorable surgical outcomes.

Tranexamic acid has emerged in the literature as a promising agent that reduces perioperative blood loss and need for transfusion. However, despite its consistently reported efficacy, low cost, and favorable safety profile, tranexamic acid remains underutilized in plastic surgery.

The investigators propose a prospective, double-blinded randomized controlled study of the efficacy of tranexamic acid in reducing hematoma development in patients undergoing reduction mammoplasty. The investigators hope to contribute to the growing body of literature supporting tranexamic acid to reduce unwanted surgical bleeding.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Montefiore Medical Center
• Collaborator: The Plastic Surgery Foundation
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Being over the age of 18

• Undergoing bilateral reduction mammoplasty at the Hutchinson Metro Center of Montefiore Medical Center, Bronx, New York

Exclusion Criteria:

• Oncologic breast reduction

• Unilateral breast reduction

• History of thromboembolic disease

• History of bleeding diatheses

• History of stroke

• History of seizure disorder

• Currently pregnant

• Severe comorbidity (defined as American Society of Anesthesiologists (ASA) fitness grade IV or above)